Literature DB >> 23627614

Prognostic value of HOXB7 mRNA expression in human oesophageal squamous cell cancer.

Xuan Xie1, Shui-shen Zhang, Jing Wen, Hong Yang, Kong-jia Luo, Fu Yang, Yi Hu, Jian-hua Fu.   

Abstract

OBJECTIVE: This study was to determine the role of HOXB7 in predicting outcomes of patients with oesophageal squamous cell cancer (OSCC).
METHODS: Samples were collected from 179 OSCC patients. HOXB7 mRNA expression was measured by quantitative real-time polymerase chain reaction.
RESULTS: HOXB7 mRNA expression was up-regulated in 85.1% of OSCC tumorous tissues, and correlated with age, pathological T and N category, as well as cancer-specific survival (CSS). However, subgroup analysis revealed its discernibility on CSS was only pronounced in early stage.
CONCLUSIONS: HOXB7 mRNA expression might serve as a novel prognostic biomarker for resected OSCC patients in early stage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23627614     DOI: 10.3109/1354750X.2013.773380

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  14 in total

1.  Overexpression of transient receptor potential vanilloid 2 is associated with poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Kun Zhou; Shui-Shen Zhang; Yan Yan; Song Zhao
Journal:  Med Oncol       Date:  2014-05-31       Impact factor: 3.064

2.  Deregulated HOXB7 Expression Predicts Poor Prognosis of Patients with Esophageal Squamous Cell Carcinoma and Regulates Cancer Cell Proliferation In Vitro and In Vivo.

Authors:  Hui Li; Lu-Yan Shen; Wan-Pu Yan; Bin Dong; Xiao-Zheng Kang; Liang Dai; Yong-Bo Yang; Hao Fu; He-Li Yang; Hai-Tao Zhou; Chuan Huang; Zhen Liang; Hong-Chao Xiong; Ke-Neng Chen
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

3.  miR-337 regulates the proliferation and invasion in pancreatic ductal adenocarcinoma by targeting HOXB7.

Authors:  Rui Zhang; Hong Leng; Junwen Huang; Yuwen Du; Yuanyuan Wang; Wenqiao Zang; Xiaonan Chen; Guoqiang Zhao
Journal:  Diagn Pathol       Date:  2014-09-03       Impact factor: 2.644

4.  HOXB7 as a promising molecular marker for metastasis in cancers: a meta-analysis.

Authors:  Fang-Teng Liu; Yang-Xi Ou; Guan-Ping Zhang; Cheng Qiu; Hong-Liang Luo; Pei-Qian Zhu
Journal:  Onco Targets Ther       Date:  2016-05-06       Impact factor: 4.147

Review 5.  Impact of homeobox genes in gastrointestinal cancer.

Authors:  Moon Kyung Joo; Jong-Jae Park; Hoon Jai Chun
Journal:  World J Gastroenterol       Date:  2016-10-07       Impact factor: 5.742

6.  HOXB7 overexpression promotes cell proliferation and correlates with poor prognosis in gastric cancer patients by inducing expression of both AKT and MARKs.

Authors:  Xujun He; Zhengchuang Liu; Yingjie Xia; Ji Xu; Guocai Lv; Lu Wang; Tonghui Ma; Liping Jiang; Yiping Mou; Xiaoting Jiang; Jie Ma; Zhongkuo Zhao; Haibin Ni; Wenjuan Xu; Guoqing Ru; Dongsheng Huang; Houquan Tao
Journal:  Oncotarget       Date:  2017-01-03

7.  Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer.

Authors:  Xuan Xie; Kongjia Luo; Yi Li; Yihong Ling; Shuishen Zhang; Xiuying Xie; Jing Wen
Journal:  Cancer Manag Res       Date:  2018-11-08       Impact factor: 3.989

8.  Targeting HOX/PBX dimer formation as a potential therapeutic option in esophageal squamous cell carcinoma.

Authors:  Lu-Yan Shen; Ting Zhou; Ya-Bing Du; Qi Shi; Ke-Neng Chen
Journal:  Cancer Sci       Date:  2019-04-05       Impact factor: 6.716

9.  Levels of HOXB7 and miR-337 in pancreatic ductal adenocarcinoma patients.

Authors:  Rui Zhang; Shangen Zheng; Yuwen Du; Yuanyuan Wang; Wenqiao Zang; Guoqiang Zhao
Journal:  Diagn Pathol       Date:  2014-03-18       Impact factor: 2.644

10.  TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma.

Authors:  Shui-Shen Zhang; Xuan Xie; Jing Wen; Kong-Jia Luo; Qian-Wen Liu; Hong Yang; Yi Hu; Jian-Hua Fu
Journal:  Diagn Pathol       Date:  2016-01-27       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.